Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluation of the Safety and Effectiveness of Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: Findings from a CIBMTR Study

  • By

  • Doris K. Hansen

  • Danai Dima

  • Hira Mian

  • Jakob Devos

  • Ruta Brazauskas

  • Temitope Oloyede

  • Aimaz Afrough

  • Nausheen Ahmed

  • Larry D. Anderson

  • Rahul Banerjee

  • Jesus G. Berdeja

  • Aram Bidikian

  • Binod Dhakal

  • Ajoy Dias

  • Yvonne Efebera

  • Muhammad Salman Faisal

  • Lohith Gowda

  • Hamza Hashmi

  • Abu-Sayeef Mirza

  • Meera Mohan

  • Ravi Narra

  • Ashley E. Rosko

  • Mark Schroeder

  • Taiga Nishihori

  • Heather Landau

  • Saad Usmani

  • Marcelo C. Pasquini

  • Othman S. Akhtar

  • Surbhi Sidana

  • Krina K. Patel

  • August 31, 2026

Share

Objective:

Correction of author name in the published article.

Key Findings:
  • The author's name was incorrectly published.
Interpretation:

The correction clarifies the authorship of the original article.

Conclusion:

The original article has undergone correction.

Sources:

Original Source(s)

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

  • by Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D. Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

  • August 31, 2026

Related Content

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report